CSPIA
INDV icon

Cary Street Partners Investment Advisory’s Indivior Pharmaceuticals INDV Stock Holding History

Cary Street Partners Investment Advisory’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-200
Closed -$4.61K – 1198
2023
Q3 		$4.61K Buy
+200
New +$4.56K ﹤0.01% 1508

Other funds holding INDV

TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Cary Street Partners Investment Advisory's INDV Position: Q4 2023 in Review

Cary Street Partners Investment Advisory sold out of Indivior Pharmaceuticals (INDV) in Q4 2023, closing a stake of 200 shares — an estimated $4.61K sold.

Cary Street Partners Investment Advisory first reported a position in INDV in Q3 2023 and held it in 1 quarter. The position peaked at $4.61K in Q3 2023. 76 funds tracked by Wall St. Rank hold INDV as of Q4 2023.

  • Cary Street Partners Investment Advisory reported no remaining Indivior Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Cary Street Partners Investment Advisory sold 200 Indivior Pharmaceuticals shares in Q4 2023, an estimated $4.61K.
  • Cary Street Partners Investment Advisory first reported a position in Indivior Pharmaceuticals in Q3 2023 and held it in 1 quarter.
  • Cary Street Partners Investment Advisory's Indivior Pharmaceuticals position peaked at $4.61K in Q3 2023.
  • 76 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q4 2023.

Based on Cary Street Partners Investment Advisory's 13F filing for Q4 2023, filed 5 Feb 2024.